From: Neurological symptoms in COVID-19: a cross-sectional monocentric study of hospitalized patients
CSF parameters | |||||||
Patient # of total 53 patients (see Additional file 1 (age) | Cells/μl (< 5) | Total Protein g/l (0.2–0.4) | Lactate mmol/l (1.1–2.4) | Glucose mg/dl (40–70) | Blood-brain-barrier dysfunction | Oligoclonal Bands (Isoelectric focussing) | SARS-CoV-2 PCR |
2 (62)a | 12 | 0.61 | 2.1 | 2 | yes | negative | negative |
20 (53) | 3 | 0.42 | 2.0 | 85 | no | negative | not available |
21 (75) | 1 | 0.18 | 1.4 | 41 | no | negative | negative |
23 (76) | 2 | 0.34 | 1.7 | 55 | no | negative | negative |
32 (69) | 10 | 0.95 | 3.5 | 87 | yes | negative | negative |
33 (59) | 12 | 0.3 | 4.3 | 83 | yes | negative | negative |
37 (56) | 2 | 0.39 | 2.2 | 80 | no | negative | negative |
45 (77) | 2 | 0.31 | 1.5 | 64 | no | negative | negative |
53 (55)a | 1 | 0.19 | 2.8 | 105 | no | negative | negative |
Specific serum analysis | |||||||
Patient # (age) | D-dimers ng/ml (< 500) | Ferritin ng/ml (15–150) | Il-2-Rc U/ml (158–623) | Il-6 pg/ml (< 7.0) | TNF-alpha pg/ml (< 8.1) | NSE ng/ml (< 17) | |
2 (62)a | 13,662 | 1497 | 6455 | 4203 | 74.1 | 26 | |
20 (53) | 292 | 232 | 452 | 22 | 10 | n.a. | |
21 (75) | 1209 | 234 | n.a. | n.a. | n.a. | n.a. | |
23 (76) | 613 | 415 | < 158 | 21 | 6.8 | n.a. | |
32 (69) | 23,237 | 2277 | 943 | 1407 | 25 | 29 | |
33 (59) | 25,243 | 6644 | 4343 | 331 | 44 | 31 | |
37 (56) | 95,052 | 3501 | 2245 | 1408 | 27 | 51 | |
45 (77) | 1170 | 1790 | 1007 | 1369 | < 8 | n.a. | |
53 (55)a | 24,754 | 5264 | n.a. | 636 | n.a. | n.a. |